Table. Reconciliation of results of current and prior meta-analyses.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Current** | **Huang**  **2019**  **PMID:** [**31296196**](http://pubmed.gov/31296196) | **Rota 2019**  **PMID:** [**31046087**](http://pubmed.gov/31046087) | **Wang 2018**  **PMID:** [**2997938**](http://pubmed.gov/2997938) | **Snowsill (NHS)\*, 2018 PMID:** [**26013989**](http://pubmed.gov/26013989) | **Coureau 2016 PMID:** [**27211572**](http://pubmed.gov/27211572) | **Usman Ali 2016**  **PMID:** [**2713053**](http://pubmed.gov/2713053) | **Fu 2014**  **PMID** [**25307063**](http://pubmed.gov/25307063) | **Manser (Cochrane), 2013 PMID** [**23794187**](http://pubmed.gov/23794187) | **Humphrey (USPSTF) 2013**  **PMID:** [**23897166**](http://pubmed.gov/23897166) |
| Number of studies | 9 | 9 | 7 | 4 | 4 | 5 | 4 | 4 | 1 | 4 |
| Efficacy for lung cancer mortality reduction | 0.84 (0.75, 0.93) | 0.83 (0.76, 0.90) | 0.80 (0.71, 0.90) | 1.13 (0.78, 1.64)  Exclude MILD  1.02 (0.66, 1.58) | 0.94 (0.74, 1.19)  Exclude MILD  0.85 (0.74, 0.98) | NA | Annual vs. usual  1.30 (0.81, 2.11)  CXR  Biennial vs. usual  1.45 (0.79, 2.69)  LDCT vs. CXR (n = 1)  0.80 (0.70, 0.92) | 0.84 (0.74, 0.96) Studies mislabeled | 0.80 (0.70, 0.92) | Meta-analysis not performed due to heterogeneity |
| Heterogeneity | 0% | 1% | 19% | 87%  Exclude MILD 85% | 43%  6.9% | NA | 40%  NA  NA | 48% | NA (1 study) | High |
| Efficacy for overall mortality reduction | 0.96 (0.91, 1.01) | 0.95 (0.90, 1.00) |  | NA | 1.00 (0.87, 1.16)  Exclude MILD  0.95 (0.89, 1.00) | NA | Annual LDCT vs. usual  1.38 (0.86, 2.22)  Biennial vs. usual 1.45 (0.79, 2.69)  LDCT vs. CXR 0.94 (0.88, 0.998) | 1.04 (0.72, 1.51)  Studies mislabeled | 0.94 (0.88, 1.00) | Meta-analysis not performed due to heterogeneity |
| Heterogeneity | 0% | 0% |  | NA | 57%  0% | NA | 80%  NA  NA | 48% | NA (1 study) | High |